• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.

作者信息

Raposo Inês, Carvalho Cláudia, Bettencourt Andreia, Da Silva Berta Martins, Leite Luiz, Selores Manuela, Torres Tiago

机构信息

Department of Dermatology, Centro Hospitalar do Porto, Portugal.

Immunogenetics laboratory, Instituto Ciências Biomédicas Abel Salazar, University of Porto, Portugal.

出版信息

Eur J Dermatol. 2017 Oct 1;27(5):528-530. doi: 10.1684/ejd.2017.3071.

DOI:10.1684/ejd.2017.3071
PMID:29084639
Abstract
摘要

相似文献

1
Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.银屑病药物遗传学：HLA - Cw*0602作为乌司奴单抗治疗反应的标志物
Eur J Dermatol. 2017 Oct 1;27(5):528-530. doi: 10.1684/ejd.2017.3071.
2
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up.HLA-C*06与白种人银屑病患者对乌司奴单抗的反应：结果与长期随访
J Am Acad Dermatol. 2016 Feb;74(2):374-5. doi: 10.1016/j.jaad.2015.08.055.
3
Interaction between Smoking and HLA-C*06:02 on the Response to Ustekinumab in Psoriasis.吸烟与HLA-C*06:02之间的相互作用对银屑病患者使用司库奇尤单抗的反应的影响
J Invest Dermatol. 2020 Aug;140(8):1653-1656.e1. doi: 10.1016/j.jid.2020.01.013. Epub 2020 Feb 1.
4
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.IL12B（p40）基因多态性有助于银屑病中乌司奴单抗疗效的预测。
Dermatology. 2016;232(2):230-6. doi: 10.1159/000441719. Epub 2015 Dec 18.
5
Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.HLA-C*06 等位基因在乌司奴单抗临床应答中的作用：来自大型欧洲患者队列的真实生活证据。
Br J Dermatol. 2017 Aug;177(2):489-496. doi: 10.1111/bjd.15387. Epub 2017 Jun 22.
6
Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis.人类白细胞抗原-Cw6 作为预测乌司奴单抗（一种白介素-12/23 阻滞剂）在中国银屑病患者临床应答的标志物：一项回顾性分析。
Br J Dermatol. 2014 Nov;171(5):1181-8. doi: 10.1111/bjd.13056. Epub 2014 Oct 15.
7
High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab.高分辨率 HLA 分型鉴定出 HLA-C*06:02 阳性银屑病患者的一个新的“超级反应者”亚组：HLA-C*06:02/HLA-C*04，针对优特克单抗治疗。
J Eur Acad Dermatol Venereol. 2019 Oct;33(10):e364-e367. doi: 10.1111/jdv.15659. Epub 2019 May 20.
8
Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis.HLA-C*06:02 等位基因状态与银屑病患者乌司奴单抗疗效差异的相关性：系统评价和荟萃分析。
JAMA Dermatol. 2019 Jun 1;155(6):708-715. doi: 10.1001/jamadermatol.2019.0098.
9
Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.中度至重度斑块状银屑病患者中优特克单抗的药物遗传学
Pharmacogenomics. 2017 Jan;18(2):157-164. doi: 10.2217/pgs-2016-0122. Epub 2016 Dec 15.
10
HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis.中国人慢性斑块状银屑病患者的 HLA 多态性：亚组分析。
Br J Dermatol. 2012 Feb;166(2):288-97. doi: 10.1111/j.1365-2133.2011.10688.x. Epub 2012 Jan 9.

引用本文的文献

1
Gene Ontology Analysis Highlights Biological Processes Influencing Responsiveness to Biological Therapy in Psoriasis.基因本体分析突出了影响银屑病生物治疗反应性的生物学过程。
Pharmaceutics. 2023 Jul 26;15(8):2024. doi: 10.3390/pharmaceutics15082024.
2
Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine.遗传因素对银屑病治疗反应的影响：个性化医学的新见解。
Int J Mol Sci. 2023 Jun 7;24(12):9850. doi: 10.3390/ijms24129850.
3
Allelic Variants of HLA-C Upstream Region, , , and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis.
HLA-C上游区域的等位基因变体以及参与表皮稳态和屏障功能的基因影响银屑病患者抗IL-12/IL-23治疗的临床反应。
Vaccines (Basel). 2022 Nov 21;10(11):1977. doi: 10.3390/vaccines10111977.
4
Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives.古塞库单抗治疗中重度银屑病的超级应答者：误区、现状与未来展望
Life (Basel). 2022 Sep 10;12(9):1412. doi: 10.3390/life12091412.
5
Towards Personalized Medicine in Psoriasis: Current Progress.银屑病的个性化医疗：当前进展
Psoriasis (Auckl). 2022 Sep 1;12:231-250. doi: 10.2147/PTT.S328460. eCollection 2022.
6
Variants in PRKCE and KLC1, Potential Regulators of Type I Psoriasis.PRKCE和KLC1基因变异，I型银屑病的潜在调控因子。
Clin Cosmet Investig Dermatol. 2022 Jul 1;15:1237-1245. doi: 10.2147/CCID.S371719. eCollection 2022.
7
Pharmacogenetics Update on Biologic Therapy in Psoriasis.银屑病生物治疗的药物遗传学最新进展。
Medicina (Kaunas). 2020 Dec 20;56(12):719. doi: 10.3390/medicina56120719.
8
Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information.对患者进行HLA-C*06:02基因分型的重要性：它不仅提供了对生物制剂药物反应的药物遗传学意义，还提供了药物生存期和药物相关成本信息。
Ann Transl Med. 2020 Aug;8(15):971. doi: 10.21037/atm.2020.04.05.
9
Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis.HLA-C*06:02 等位基因状态与银屑病患者乌司奴单抗疗效差异的相关性：系统评价和荟萃分析。
JAMA Dermatol. 2019 Jun 1;155(6):708-715. doi: 10.1001/jamadermatol.2019.0098.